Vote Scores

Home / Companies / Jiangsu Hengrui Pharmaceuticals Co., Ltd. / 15 May 2024

Meeting · year to 30 June 202449 filers reporting

Jiangsu Hengrui Pharmaceuticals Co., Ltd.: meeting of 15 May 2024

Votes reported on Form N-PX, item by item

49 Form N-PX filers reported votes at the Jiangsu Hengrui Pharmaceuticals Co., Ltd. meeting of 15 May 2024. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

90 vote records from 49 filers. 0 of the 49 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management49 filers100.0% for0.0% against0.0% other0.0% against management71,384,587 reported shares
2

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

90 vote records from 49 filers. 0 of the 49 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management49 filers100.0% for0.0% against0.0% against management71,384,587 reported shares, counted once per item in this group
3

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

180 vote records from 49 filers. 0 of the 49 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management49 filers100.0% for0.0% against0.0% against management142,769,174 reported shares, counted once per item in this group
4

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

320 vote records from 42 filers. 0 of the 42 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management42 filers100.0% for0.0% against0.0% against management279,969,836 reported shares, counted once per item in this group
5

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

40 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management7 filers100.0% for0.0% against0.0% against management5,568,512 reported shares, counted once per item in this group

How the largest families voted

Family1. Auditor
VanguardFor
BlackRock and iSharesFor
FidelityFor
DimensionalFor
State Street and SPDRFor
Franklin TempletonFor
EquitableFor
Nuveen and TIAAFor
John Hancock and ManulifeFor
Morgan Stanley, Eaton Vance and CalvertFor
J.P. MorganFor
WisdomTreeFor
Jackson National fundsFor
Northern Trust and FlexSharesFor
Lincoln FinancialFor
VoyaFor
BNY MellonFor
Capital Group and American FundsFor
Pacific Life fundsFor
PIMCOFor
Dodge & CoxFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Jiangsu Hengrui Pharmaceuticals Co., Ltd. meeting?

49 Form N-PX filers reported votes at the meeting of 15 May 2024. The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Jiangsu Hengrui Pharmaceuticals Co., Ltd. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Jiangsu Hengrui Pharmaceuticals Co., Ltd. with a meeting date within three days of 15 May 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.